Vitrasert Implant (ganciclovir)
- Region
- 🇪🇺 EU
- Active substance
- ganciclovir
- Company
- Dr. Gerhard Mann, Chem.-Pharm. Fabrik GmbH..
- Status
- Withdrawn
- Therapeutic area
- Cytomegalovirus Retinitis; HIV Infections
- EU approval
- Tue 18 Mar 1997
- Application
- EMEA/H/C/000120
- ATC
- J05AB06
- Official record
- www.ema.europa.eu
Indication
The Vitrasert implant is indicated for the local treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS) (See 4.4. Special warnings and special precautions for use).
Regulatory milestones
No milestones recorded in the last year.
Follow Vitrasert Implant
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.